Fibrolamellar Carcinoma in the Molecular Era: From DNAJB1::PRKACA Biology to Precision Therapeutic Strategies. (PubMed, J Gastrointest Cancer) - Oct 4, 2026 - "The molecular characterization of FLC has established a rationale for fusion-directed therapeutic development. Current care should integrate molecular confirmation, multidisciplinary management, and early clinical trial referral, consistent with the 2026 guideline."
Journal • Review • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • DNAJB1 • PRKACA
|